Abstract

We determined the incidence and outcome of aplastic anemia among 56 patients who underwent liver transplantation for fulminant liver failure at the University of Nebraska Medical Center between July 1985 and December 1993. Aplastic anemia developed in 6 of 18 (33%) children and 1 of 19 (5%) adults who had fulminant non‐A, non‐B hepatitis; no cases of aplastic anemia occurred among patients with other causes of fulminant liver failure. None of these patients had evidence of a preexisting hematological disorder or in fection with hepatitis C virus (as determined with a second‐generation ELISA). Aplastic anemia was diagnosed at a median of 4 wk after the onset of hepatitis, with five cases seen before transplantation. Six patients received antithymocyte globulin to promote remission of aplastic anemia. Three children died (fungal infection in two, intracranial hemorrhage in one)—one at 43, one at 108 and one at 119 days after transplantation—without remission of aplastic anemia. Among the four surviving patients, with median follow‐up of 25 mo, complete and partial remission of aplastic anemia have occurred in three and one, respectively. Liver allograft function is stable in all surviving patients. The data demonstrate that aplastic anemia is a common complication among children who undergo liver transplantation for fulminant non‐A, non‐B hepatitis. It is associated with a high rate of mortality, although most survivors appear to have full hematological recovery. (Hepatology 1994;20:813‐818).

Original languageEnglish (US)
Pages (from-to)813-818
Number of pages6
JournalHepatology
Volume20
Issue number4
DOIs
StatePublished - Oct 1994

Fingerprint

Acute Liver Failure
Aplastic Anemia
Liver Transplantation
Hepatitis
Preexisting Condition Coverage
Antilymphocyte Serum
Mycoses
Intracranial Hemorrhages
Gastroenterology
Hepacivirus
Allografts
Survivors
Transplantation
Enzyme-Linked Immunosorbent Assay
Mortality
Liver
Incidence

ASJC Scopus subject areas

  • Hepatology

Cite this

Cattral, M. S., Langnas, A. N., Markin, R. S., Antonson, D. L., Heffron, T. G., Fox, I. J., ... Shaw, B. W. (1994). Aplastic anemia after liver transplantation for fulminant liver failure. Hepatology, 20(4), 813-818. https://doi.org/10.1002/hep.1840200407

Aplastic anemia after liver transplantation for fulminant liver failure. / Cattral, Mark S.; Langnas, Alan Norman; Markin, Rodney Smith; Antonson, Dean L.; Heffron, Thomas G.; Fox, Ira J.; Sorrell, Michael Floyd; Shaw, Byers W.

In: Hepatology, Vol. 20, No. 4, 10.1994, p. 813-818.

Research output: Contribution to journalArticle

Cattral, Mark S. ; Langnas, Alan Norman ; Markin, Rodney Smith ; Antonson, Dean L. ; Heffron, Thomas G. ; Fox, Ira J. ; Sorrell, Michael Floyd ; Shaw, Byers W. / Aplastic anemia after liver transplantation for fulminant liver failure. In: Hepatology. 1994 ; Vol. 20, No. 4. pp. 813-818.
@article{ce908561a5fa49a0aa03d2a538cfaf83,
title = "Aplastic anemia after liver transplantation for fulminant liver failure",
abstract = "We determined the incidence and outcome of aplastic anemia among 56 patients who underwent liver transplantation for fulminant liver failure at the University of Nebraska Medical Center between July 1985 and December 1993. Aplastic anemia developed in 6 of 18 (33{\%}) children and 1 of 19 (5{\%}) adults who had fulminant non‐A, non‐B hepatitis; no cases of aplastic anemia occurred among patients with other causes of fulminant liver failure. None of these patients had evidence of a preexisting hematological disorder or in fection with hepatitis C virus (as determined with a second‐generation ELISA). Aplastic anemia was diagnosed at a median of 4 wk after the onset of hepatitis, with five cases seen before transplantation. Six patients received antithymocyte globulin to promote remission of aplastic anemia. Three children died (fungal infection in two, intracranial hemorrhage in one)—one at 43, one at 108 and one at 119 days after transplantation—without remission of aplastic anemia. Among the four surviving patients, with median follow‐up of 25 mo, complete and partial remission of aplastic anemia have occurred in three and one, respectively. Liver allograft function is stable in all surviving patients. The data demonstrate that aplastic anemia is a common complication among children who undergo liver transplantation for fulminant non‐A, non‐B hepatitis. It is associated with a high rate of mortality, although most survivors appear to have full hematological recovery. (Hepatology 1994;20:813‐818).",
author = "Cattral, {Mark S.} and Langnas, {Alan Norman} and Markin, {Rodney Smith} and Antonson, {Dean L.} and Heffron, {Thomas G.} and Fox, {Ira J.} and Sorrell, {Michael Floyd} and Shaw, {Byers W.}",
year = "1994",
month = "10",
doi = "10.1002/hep.1840200407",
language = "English (US)",
volume = "20",
pages = "813--818",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Aplastic anemia after liver transplantation for fulminant liver failure

AU - Cattral, Mark S.

AU - Langnas, Alan Norman

AU - Markin, Rodney Smith

AU - Antonson, Dean L.

AU - Heffron, Thomas G.

AU - Fox, Ira J.

AU - Sorrell, Michael Floyd

AU - Shaw, Byers W.

PY - 1994/10

Y1 - 1994/10

N2 - We determined the incidence and outcome of aplastic anemia among 56 patients who underwent liver transplantation for fulminant liver failure at the University of Nebraska Medical Center between July 1985 and December 1993. Aplastic anemia developed in 6 of 18 (33%) children and 1 of 19 (5%) adults who had fulminant non‐A, non‐B hepatitis; no cases of aplastic anemia occurred among patients with other causes of fulminant liver failure. None of these patients had evidence of a preexisting hematological disorder or in fection with hepatitis C virus (as determined with a second‐generation ELISA). Aplastic anemia was diagnosed at a median of 4 wk after the onset of hepatitis, with five cases seen before transplantation. Six patients received antithymocyte globulin to promote remission of aplastic anemia. Three children died (fungal infection in two, intracranial hemorrhage in one)—one at 43, one at 108 and one at 119 days after transplantation—without remission of aplastic anemia. Among the four surviving patients, with median follow‐up of 25 mo, complete and partial remission of aplastic anemia have occurred in three and one, respectively. Liver allograft function is stable in all surviving patients. The data demonstrate that aplastic anemia is a common complication among children who undergo liver transplantation for fulminant non‐A, non‐B hepatitis. It is associated with a high rate of mortality, although most survivors appear to have full hematological recovery. (Hepatology 1994;20:813‐818).

AB - We determined the incidence and outcome of aplastic anemia among 56 patients who underwent liver transplantation for fulminant liver failure at the University of Nebraska Medical Center between July 1985 and December 1993. Aplastic anemia developed in 6 of 18 (33%) children and 1 of 19 (5%) adults who had fulminant non‐A, non‐B hepatitis; no cases of aplastic anemia occurred among patients with other causes of fulminant liver failure. None of these patients had evidence of a preexisting hematological disorder or in fection with hepatitis C virus (as determined with a second‐generation ELISA). Aplastic anemia was diagnosed at a median of 4 wk after the onset of hepatitis, with five cases seen before transplantation. Six patients received antithymocyte globulin to promote remission of aplastic anemia. Three children died (fungal infection in two, intracranial hemorrhage in one)—one at 43, one at 108 and one at 119 days after transplantation—without remission of aplastic anemia. Among the four surviving patients, with median follow‐up of 25 mo, complete and partial remission of aplastic anemia have occurred in three and one, respectively. Liver allograft function is stable in all surviving patients. The data demonstrate that aplastic anemia is a common complication among children who undergo liver transplantation for fulminant non‐A, non‐B hepatitis. It is associated with a high rate of mortality, although most survivors appear to have full hematological recovery. (Hepatology 1994;20:813‐818).

UR - http://www.scopus.com/inward/record.url?scp=0028101315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028101315&partnerID=8YFLogxK

U2 - 10.1002/hep.1840200407

DO - 10.1002/hep.1840200407

M3 - Article

C2 - 7927220

AN - SCOPUS:0028101315

VL - 20

SP - 813

EP - 818

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 4

ER -